A brief cognitive assessment for use with schizophrenia patients in community clinics

被引:58
作者
Velligan, DI
DiCocco, M
Bow-Thomas, CC
Cadle, C
Glahn, DC
Miller, AL
Biggs, MM
Shores-Wilson, K
McKenzie, CA
Crismon, ML
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA
[2] San Antonio State Hosp, Clin Res Unit, San Antonio, TX USA
[3] Univ Texas, Med Ctr, Dept Psychiat, Dallas, TX 75230 USA
[4] Univ Texas, Coll Pharm, Austin, TX 78712 USA
[5] Texas Dept Mental Hlth & Mental Retardat, Austin, TX USA
关键词
brief cognitive assessment; schizophrenia; cognitive impairments;
D O I
10.1016/j.schres.2004.02.027
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Cognitive impairment is a prominent feature of schizophrenia. The availability of very brief measures may increase the use of cognitive assessment in routine care settings. We examined the reliability and validity of the brief cognitive assessment (BCA), a battery that takes approximately 15 min to administer and score, and that was designed to be sensitive to changes in cognition with novel antipsychotics. The BCA was administered to 340 outpatients on two occasions, 3 months apart. A sub-sample of subjects received a full battery of cognitive tests (n = 97) and additional measures of functional outcome. Results indicated that the BCA had very good test-retest reliability and inter-item consistency. Moreover, the BCA was strongly correlated with a comprehensive battery (r = 0.72; p < 0.0001) which took 8 to 10 times longer to administer. Finally, both cognitive batteries were correlated similarly with measures of community functioning. Changes over time for individual patients can be interpreted in the context of normative data available for each test in the BCA. The data provide preliminary evidence for the reliability and validity of the BCA. Further studies examining the utility of the BCA for tracking changes in cognitive functioning with treatment are encouraged. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:273 / 283
页数:11
相关论文
共 51 条
[1]   Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo [J].
Arvanitis, LA ;
Miller, BG ;
Borison, RL ;
Pitts, WM ;
Sharif, ZA ;
Hamner, MB ;
Herz, MI ;
True, JE ;
Velligan, D ;
Knesevich, MA ;
Small, J ;
Steinbook, R ;
Hertzman, M ;
Keck, PE ;
Newcomer, JW ;
Grace, J ;
Rotrosen, J ;
Tandon, R ;
Dott, SG ;
Ferguson, JM ;
Addington, DEN ;
MacEwan, GW ;
Nair, VNP ;
Shriqui, CL ;
Williams, R ;
Daniel, DG ;
Shehi, GM ;
Patterson, WM ;
Merideth, CH .
BIOLOGICAL PSYCHIATRY, 1997, 42 (04) :233-246
[2]   A COMMUNITY ABILITY SCALE FOR CHRONICALLY MENTALLY-ILL CONSUMERS .1. RELIABILITY AND VALIDITY [J].
BARKER, S ;
BARRON, N ;
MCFARLAND, BH ;
BIGELOW, DA .
COMMUNITY MENTAL HEALTH JOURNAL, 1994, 30 (04) :363-379
[3]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[4]  
Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]
[5]  
Cohen TJ, 1988, STAT POWER ANAL BEHA
[6]  
Delis D. C., 1987, California Verbal Learning Test Manual, DOI [10.1037/t15072-000, DOI 10.1037/T15072-000]
[7]  
DOMBROWSKI SB, 1990, FUNCTIONAL NEEDS ASS
[8]   Texas medication algorithm project: Definitions, rationale, and methods to develop medication algorithms [J].
Gilbert, DA ;
Altshuler, KZ ;
Rago, WV ;
Shon, SP ;
Crismon, L ;
Toprac, MG ;
Rush, AJ .
JOURNAL OF CLINICAL PSYCHIATRY, 1998, 59 (07) :345-351
[9]  
Gold JM, 1999, AM J PSYCHIAT, V156, P1944
[10]  
GOLD JM, 2002, 42 ANN NCDEU M BOC R